
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Histamine Dihydrochloride,Interleukin 2
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Delbert Lab
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Ceplene® demonstrated a clinical interest in maintenance treatment of acute myeloid leukemia (AML) in patients below 60 years of age in first "complete remission" (symptom-free period of disease after initial treatment) in a clinical study.
Product Name : Ceplene
Product Type : Amino Acid
Upfront Cash : Undisclosed
November 18, 2022
Lead Product(s) : Histamine Dihydrochloride,Interleukin 2
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Delbert Lab
Deal Size : Undisclosed
Deal Type : Acquisition
